Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. more
Time Frame | COGT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.08% | 1.76% | -2.37% |
1-Month Return | -7.12% | 0.33% | -3.79% |
3-Month Return | -33.07% | -8.58% | -0.46% |
6-Month Return | -18.16% | -4.26% | 3.58% |
1-Year Return | 60.38% | 1.27% | 22.47% |
3-Year Return | -5.37% | 5.33% | 25.17% |
5-Year Return | 117.8% | 38.09% | 77.46% |
10-Year Return | -82.97% | 102.29% | 188.42% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 22.50M | 7.87M | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.98,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 43.71K | 25.74K | 147.00K | 5.88M | 3.59M | [{"date":"2019-12-31","value":0.74,"profit":true},{"date":"2020-12-31","value":0.44,"profit":true},{"date":"2021-12-31","value":2.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":61.04,"profit":true}] |
Gross Profit | 22.50M | 7.85M | (147.00K) | (5.88M) | (3.59M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.87,"profit":true},{"date":"2021-12-31","value":-0.65,"profit":false},{"date":"2022-12-31","value":-26.13,"profit":false},{"date":"2023-12-31","value":-15.95,"profit":false}] |
Gross Margin | 100.00% | 99.67% | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.67,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 54.68M | 90.07M | 75.55M | 147.84M | 208.13M | [{"date":"2019-12-31","value":26.27,"profit":true},{"date":"2020-12-31","value":43.28,"profit":true},{"date":"2021-12-31","value":36.3,"profit":true},{"date":"2022-12-31","value":71.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (32.18M) | (82.20M) | (75.55M) | (147.84M) | (208.13M) | [{"date":"2019-12-31","value":-3217800000,"profit":false},{"date":"2020-12-31","value":-8219900000,"profit":false},{"date":"2021-12-31","value":-7555100000,"profit":false},{"date":"2022-12-31","value":-14783900000,"profit":false},{"date":"2023-12-31","value":-20813000000,"profit":false}] |
Total Non-Operating Income/Expense | 612.00K | 7.54M | 3.75M | 11.59M | 27.04M | [{"date":"2019-12-31","value":2.26,"profit":true},{"date":"2020-12-31","value":27.87,"profit":true},{"date":"2021-12-31","value":13.85,"profit":true},{"date":"2022-12-31","value":42.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (31.83M) | (74.81M) | (72.27M) | (140.24M) | (192.41M) | [{"date":"2019-12-31","value":-3183300000,"profit":false},{"date":"2020-12-31","value":-7480800000,"profit":false},{"date":"2021-12-31","value":-7227300000,"profit":false},{"date":"2022-12-31","value":-14024100000,"profit":false},{"date":"2023-12-31","value":-19241000000,"profit":false}] |
Income Taxes | (1.56M) | (8.36M) | (467.00K) | (7.60M) | - | [{"date":"2019-12-31","value":-156000000,"profit":false},{"date":"2020-12-31","value":-835700000,"profit":false},{"date":"2021-12-31","value":-46700000,"profit":false},{"date":"2022-12-31","value":-759800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (30.27M) | (66.45M) | (71.81M) | (132.64M) | - | [{"date":"2019-12-31","value":-3027300000,"profit":false},{"date":"2020-12-31","value":-6645100000,"profit":false},{"date":"2021-12-31","value":-7180600000,"profit":false},{"date":"2022-12-31","value":-13264300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (31.83M) | (74.81M) | (72.27M) | (140.24M) | (177.66M) | [{"date":"2019-12-31","value":-3183300000,"profit":false},{"date":"2020-12-31","value":-7480800000,"profit":false},{"date":"2021-12-31","value":-7227300000,"profit":false},{"date":"2022-12-31","value":-14024100000,"profit":false},{"date":"2023-12-31","value":-17766300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (30.27M) | (66.45M) | (71.81M) | (132.64M) | (192.41M) | [{"date":"2019-12-31","value":-3027300000,"profit":false},{"date":"2020-12-31","value":-6645100000,"profit":false},{"date":"2021-12-31","value":-7180600000,"profit":false},{"date":"2022-12-31","value":-13264300000,"profit":false},{"date":"2023-12-31","value":-19241000000,"profit":false}] |
EPS (Diluted) | (4.20) | (8.10) | (1.85) | (2.45) | (2.40) | [{"date":"2019-12-31","value":-420,"profit":false},{"date":"2020-12-31","value":-810,"profit":false},{"date":"2021-12-31","value":-185,"profit":false},{"date":"2022-12-31","value":-245,"profit":false},{"date":"2023-12-31","value":-240,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
COGT | |
---|---|
Cash Ratio | 6.32 |
Current Ratio | 6.44 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
COGT | |
---|---|
ROA (LTM) | -44.02% |
ROE (LTM) | -78.47% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
COGT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
COGT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1320.63 |
P/B | 4.24 |
Price/FCF | NM |
EV/R | 925.41 |
EV/Ebitda | NM |
Cogent Biosciences Inc (COGT) share price today is $7.49
Yes, Indians can buy shares of Cogent Biosciences Inc (COGT) on Vested. To buy Cogent Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COGT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cogent Biosciences Inc (COGT) via the Vested app. You can start investing in Cogent Biosciences Inc (COGT) with a minimum investment of $1.
You can invest in shares of Cogent Biosciences Inc (COGT) via Vested in three simple steps:
The 52-week high price of Cogent Biosciences Inc (COGT) is $12.61. The 52-week low price of Cogent Biosciences Inc (COGT) is $4.28.
The price-to-earnings (P/E) ratio of Cogent Biosciences Inc (COGT) is
The price-to-book (P/B) ratio of Cogent Biosciences Inc (COGT) is 4.24
The dividend yield of Cogent Biosciences Inc (COGT) is 0.00%
The market capitalization of Cogent Biosciences Inc (COGT) is $821.84M
The stock symbol (or ticker) of Cogent Biosciences Inc is COGT